US20190382363A1 - Aryl sulfonamides as blt1 antagonists - Google Patents
Aryl sulfonamides as blt1 antagonists Download PDFInfo
- Publication number
- US20190382363A1 US20190382363A1 US15/768,880 US201615768880A US2019382363A1 US 20190382363 A1 US20190382363 A1 US 20190382363A1 US 201615768880 A US201615768880 A US 201615768880A US 2019382363 A1 US2019382363 A1 US 2019382363A1
- Authority
- US
- United States
- Prior art keywords
- phenyl
- hydroxy
- trifluoro
- methanesulfonamide
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZVTFUSBAPXUAGO-UHFFFAOYSA-N *.B.CC.CC.CC1=CC2=C(C=C1)C(O)C(C(C)(C)C)CO2 Chemical compound *.B.CC.CC.CC1=CC2=C(C=C1)C(O)C(C(C)(C)C)CO2 ZVTFUSBAPXUAGO-UHFFFAOYSA-N 0.000 description 11
- RVTQLIUKWIBLCA-UHFFFAOYSA-N *.CC.CC.CC(C)(C)C1COC2=C(C=CC(C3=CC=CC=C3)=C2)C1O Chemical compound *.CC.CC.CC(C)(C)C1COC2=C(C=CC(C3=CC=CC=C3)=C2)C1O RVTQLIUKWIBLCA-UHFFFAOYSA-N 0.000 description 4
- MEZSEZOZACTRKR-UHFFFAOYSA-N *.CC.CC1=C(C2=CC3=C(C=C2)C(O)C(C(C)(C)C)CO3)C=CC=C1 Chemical compound *.CC.CC1=C(C2=CC3=C(C=C2)C(O)C(C(C)(C)C)CO3)C=CC=C1 MEZSEZOZACTRKR-UHFFFAOYSA-N 0.000 description 4
- YHKWELIZMYMUEB-KDYSTLNUSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=C(C4=CC=CC=C4)C=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=C(C4=CC=CC=C4)C=N2)[C@H]3O)C=CC=C1)C(F)(F)F YHKWELIZMYMUEB-KDYSTLNUSA-N 0.000 description 3
- 0 BC(*)(CCCCCCCCC1)CC1c1ccc(C(C(CO2)C(*)(C3CCCCCCCCCC3)O*)O)c2c1 Chemical compound BC(*)(CCCCCCCCC1)CC1c1ccc(C(C(CO2)C(*)(C3CCCCCCCCCC3)O*)O)c2c1 0.000 description 2
- CWKUGXXPYIMESR-KSFYIVLOSA-N CC1=CC=CN=C1C[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O Chemical compound CC1=CC=CN=C1C[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O CWKUGXXPYIMESR-KSFYIVLOSA-N 0.000 description 2
- XMKBRYVDGNDSKT-VLIAUNLRSA-N CC1=CN=C(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)S1 Chemical compound CC1=CN=C(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)S1 XMKBRYVDGNDSKT-VLIAUNLRSA-N 0.000 description 2
- OIAIWPGZTBOTSU-VLIAUNLRSA-N CC1=NC(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)=CS1 Chemical compound CC1=NC(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)=CS1 OIAIWPGZTBOTSU-VLIAUNLRSA-N 0.000 description 2
- GHPRXTJTJZTZHE-YCRPNKLZSA-N CCN1C=CC(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=N1 Chemical compound CCN1C=CC(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=N1 GHPRXTJTJZTZHE-YCRPNKLZSA-N 0.000 description 2
- WXNYPIPBZUVKBW-UHFFFAOYSA-N CN1N=CC=C1CC1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2C1O Chemical compound CN1N=CC=C1CC1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2C1O WXNYPIPBZUVKBW-UHFFFAOYSA-N 0.000 description 2
- ZFKVSPRBUMBGNI-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=CS2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=CS2)C3O)C=CC=C1 ZFKVSPRBUMBGNI-UHFFFAOYSA-N 0.000 description 2
- IWCDTDLEWGZBRX-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)C=C2)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)C=C2)C3O)C=CC=C1)C(F)(F)F IWCDTDLEWGZBRX-UHFFFAOYSA-N 0.000 description 2
- VTQITGOGAOKOPN-LUTIACGYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC(C4=CC=CC=C4)=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC(C4=CC=CC=C4)=N2)[C@@H]3O)C=CC=C1)C(F)(F)F VTQITGOGAOKOPN-LUTIACGYSA-N 0.000 description 2
- VTQITGOGAOKOPN-VCUSLETLSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC(C4=CC=CC=C4)=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC(C4=CC=CC=C4)=N2)[C@H]3O)C=CC=C1)C(F)(F)F VTQITGOGAOKOPN-VCUSLETLSA-N 0.000 description 2
- YHKWELIZMYMUEB-ZBLYBZFDSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=C(C4=CC=CC=C4)C=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=C(C4=CC=CC=C4)C=N2)[C@@H]3O)C=CC=C1)C(F)(F)F YHKWELIZMYMUEB-ZBLYBZFDSA-N 0.000 description 2
- ZTWUHDQWQOWCFB-VFNWGFHPSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CSC(C4CC4)=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CSC(C4CC4)=N2)[C@@H]3O)C=CC=C1)C(F)(F)F ZTWUHDQWQOWCFB-VFNWGFHPSA-N 0.000 description 2
- GAJZEODSTKDFQN-BXKMTCNYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CN(C4=CC=CC=C4)N=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CN(C4=CC=CC=C4)N=N2)[C@H]3O)C=CC=C1)C(F)(F)F GAJZEODSTKDFQN-BXKMTCNYSA-N 0.000 description 2
- RKQFOZDZWOAFRX-MHECFPHRSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CN=C(C4=CC=CC=C4)S2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CN=C(C4=CC=CC=C4)S2)[C@H]3O)C=CC=C1)C(F)(F)F RKQFOZDZWOAFRX-MHECFPHRSA-N 0.000 description 2
- QRWHQIIQBIDPQZ-SZNDQCEHSA-N O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)[C@@H](O)[C@H](CC1=CC=C(F)C=N1)CO2)C(F)(F)F Chemical compound O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)[C@@H](O)[C@H](CC1=CC=C(F)C=N1)CO2)C(F)(F)F QRWHQIIQBIDPQZ-SZNDQCEHSA-N 0.000 description 2
- SIRGHJGHAHZBRX-XOWQENDTSA-N *.*.B.B.C.CC.CC.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@@H](C(C)(C)C)CO2.CC1=CC2=C(C=C1)[C@H](O)[C@H](C(C)(C)C)CO2 Chemical compound *.*.B.B.C.CC.CC.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@@H](C(C)(C)C)CO2.CC1=CC2=C(C=C1)[C@H](O)[C@H](C(C)(C)C)CO2 SIRGHJGHAHZBRX-XOWQENDTSA-N 0.000 description 1
- SIRGHJGHAHZBRX-HANZTJFCSA-N *.*.B.B.C.CC.CC.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@H](C(C)(C)C)CO2.CC1=CC2=C(C=C1)[C@H](O)[C@@H](C(C)(C)C)CO2 Chemical compound *.*.B.B.C.CC.CC.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@H](C(C)(C)C)CO2.CC1=CC2=C(C=C1)[C@H](O)[C@@H](C(C)(C)C)CO2 SIRGHJGHAHZBRX-HANZTJFCSA-N 0.000 description 1
- ZVTFUSBAPXUAGO-BGUZPLMTSA-N *.B.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@@H](C(C)(C)C)CO2 Chemical compound *.B.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@@H](C(C)(C)C)CO2 ZVTFUSBAPXUAGO-BGUZPLMTSA-N 0.000 description 1
- ZVTFUSBAPXUAGO-GFLHRFLJSA-N *.B.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@H](C(C)(C)C)CO2 Chemical compound *.B.CC.CC.CC1=CC2=C(C=C1)[C@@H](O)[C@H](C(C)(C)C)CO2 ZVTFUSBAPXUAGO-GFLHRFLJSA-N 0.000 description 1
- ZVTFUSBAPXUAGO-JIRZHPJNSA-N *.B.CC.CC.CC1=CC2=C(C=C1)[C@H](O)[C@@H](C(C)(C)C)CO2 Chemical compound *.B.CC.CC.CC1=CC2=C(C=C1)[C@H](O)[C@@H](C(C)(C)C)CO2 ZVTFUSBAPXUAGO-JIRZHPJNSA-N 0.000 description 1
- ZVTFUSBAPXUAGO-JSFYYTPOSA-N *.B.CC.CC.CC1=CC2=C(C=C1)[C@H](O)[C@H](C(C)(C)C)CO2 Chemical compound *.B.CC.CC.CC1=CC2=C(C=C1)[C@H](O)[C@H](C(C)(C)C)CO2 ZVTFUSBAPXUAGO-JSFYYTPOSA-N 0.000 description 1
- MZTZDFPZCKQQBC-NQRXDKCUSA-L C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.Cl[Pd]Cl.O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)[C@H]3O)C=CN=N1)C(F)(F)F.O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=C(Cl)N=N1)C(F)(F)F Chemical compound C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.Cl[Pd]Cl.O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)[C@H]3O)C=CN=N1)C(F)(F)F.O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=C(Cl)N=N1)C(F)(F)F MZTZDFPZCKQQBC-NQRXDKCUSA-L 0.000 description 1
- AHASPASQKNTEPQ-UHFFFAOYSA-N CC(C)(C)C1=NC(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3C2O)=CS1 Chemical compound CC(C)(C)C1=NC(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3C2O)=CS1 AHASPASQKNTEPQ-UHFFFAOYSA-N 0.000 description 1
- QRXUBDGWBGQLPH-LZCYTSNMSA-N CC(C1=CC=CC=N1)C1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.C[C@@H](C1=CC=CC=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.C[C@H](C1=CC=CC=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.O=C1CCOC2=CC(Br)=CC=C12.O=CC1=CC=CC=N1 Chemical compound CC(C1=CC=CC=N1)C1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.C[C@@H](C1=CC=CC=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.C[C@H](C1=CC=CC=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.O=C1CCOC2=CC(Br)=CC=C12.O=CC1=CC=CC=N1 QRXUBDGWBGQLPH-LZCYTSNMSA-N 0.000 description 1
- IZNHRGKSYPFBNA-UQIHBHLASA-N CC(C1=CSC(C2=CC=CC=C2)=N1)C1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@H]1O.C[C@@H](C1=CSC(C2=CC=CC=C2)=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O.C[C@@H](C1=CSC(C2=CC=CC=C2)=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O.C[C@H](C1=CSC(C2=CC=CC=C2)=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O Chemical compound CC(C1=CSC(C2=CC=CC=C2)=N1)C1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@H]1O.C[C@@H](C1=CSC(C2=CC=CC=C2)=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O.C[C@@H](C1=CSC(C2=CC=CC=C2)=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O.C[C@H](C1=CSC(C2=CC=CC=C2)=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O IZNHRGKSYPFBNA-UQIHBHLASA-N 0.000 description 1
- CIYZPZVIHLRJRS-MVFVFGCZSA-N CC1(C)OB(C2=CC3=C(C=C2)[C@@H](O)[C@H](CC2=CC=CC=N2)CO3)OC1(C)C.CC1(C)OB(C2=CC3=C(C=C2)[C@H](O)[C@@H](CC2=CC=CC=N2)CO3)OC1(C)C Chemical compound CC1(C)OB(C2=CC3=C(C=C2)[C@@H](O)[C@H](CC2=CC=CC=N2)CO3)OC1(C)C.CC1(C)OB(C2=CC3=C(C=C2)[C@H](O)[C@@H](CC2=CC=CC=N2)CO3)OC1(C)C CIYZPZVIHLRJRS-MVFVFGCZSA-N 0.000 description 1
- SLXGPDBYXMURIB-UHFFFAOYSA-N CC1(S(=O)(=O)NC2=C(C3=CC=C4C(=C3)OCC(CC3=CC=CC=N3)C4O)C=CC=C2)CC1 Chemical compound CC1(S(=O)(=O)NC2=C(C3=CC=C4C(=C3)OCC(CC3=CC=CC=N3)C4O)C=CC=C2)CC1 SLXGPDBYXMURIB-UHFFFAOYSA-N 0.000 description 1
- ICFPENPHMZXJDN-UHFFFAOYSA-N CC1=CC=C(CC2COC3=CC(C4=C(NS(C)(=O)=O)C=CC=C4)=CC=C3C2O)N=C1 Chemical compound CC1=CC=C(CC2COC3=CC(C4=C(NS(C)(=O)=O)C=CC=C4)=CC=C3C2O)N=C1 ICFPENPHMZXJDN-UHFFFAOYSA-N 0.000 description 1
- CWKUGXXPYIMESR-ZHRRBRCNSA-N CC1=CC=CN=C1C[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O Chemical compound CC1=CC=CN=C1C[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O CWKUGXXPYIMESR-ZHRRBRCNSA-N 0.000 description 1
- XMKBRYVDGNDSKT-YBMSBYLISA-N CC1=CN=C(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)S1 Chemical compound CC1=CN=C(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)S1 XMKBRYVDGNDSKT-YBMSBYLISA-N 0.000 description 1
- XMKBRYVDGNDSKT-VBKZILBWSA-N CC1=CN=C(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)S1 Chemical compound CC1=CN=C(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)S1 XMKBRYVDGNDSKT-VBKZILBWSA-N 0.000 description 1
- BOUQUERBEJOEDQ-UHFFFAOYSA-N CC1=NC(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3C2O)=CC=C1 Chemical compound CC1=NC(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3C2O)=CC=C1 BOUQUERBEJOEDQ-UHFFFAOYSA-N 0.000 description 1
- OIAIWPGZTBOTSU-YBMSBYLISA-N CC1=NC(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=CS1 Chemical compound CC1=NC(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=CS1 OIAIWPGZTBOTSU-YBMSBYLISA-N 0.000 description 1
- BOUQUERBEJOEDQ-ZHRRBRCNSA-N CC1=NC(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)=CC=C1 Chemical compound CC1=NC(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)=CC=C1 BOUQUERBEJOEDQ-ZHRRBRCNSA-N 0.000 description 1
- BOUQUERBEJOEDQ-KSFYIVLOSA-N CC1=NC(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=CC=C1 Chemical compound CC1=NC(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=CC=C1 BOUQUERBEJOEDQ-KSFYIVLOSA-N 0.000 description 1
- OIAIWPGZTBOTSU-VBKZILBWSA-N CC1=NC(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=CS1 Chemical compound CC1=NC(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)=CS1 OIAIWPGZTBOTSU-VBKZILBWSA-N 0.000 description 1
- JDMURWPXKVFIID-UHFFFAOYSA-N CC1=NN=C(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3C2O)S1 Chemical compound CC1=NN=C(CC2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3C2O)S1 JDMURWPXKVFIID-UHFFFAOYSA-N 0.000 description 1
- JDMURWPXKVFIID-YJYMSZOUSA-N CC1=NN=C(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)S1 Chemical compound CC1=NN=C(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)S1 JDMURWPXKVFIID-YJYMSZOUSA-N 0.000 description 1
- JDMURWPXKVFIID-ORAYPTAESA-N CC1=NN=C(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)S1 Chemical compound CC1=NN=C(C[C@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@@H]2O)S1 JDMURWPXKVFIID-ORAYPTAESA-N 0.000 description 1
- GHPRXTJTJZTZHE-VFNWGFHPSA-N CCN1C=CC(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)=N1 Chemical compound CCN1C=CC(C[C@@H]2COC3=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=CC=C3[C@H]2O)=N1 GHPRXTJTJZTZHE-VFNWGFHPSA-N 0.000 description 1
- DWHYXLJHJYJIMZ-VLIAUNLRSA-N CN1C=CC(C[C@@H]2COC3=C(C=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=C3)[C@H]2O)=N1 Chemical compound CN1C=CC(C[C@@H]2COC3=C(C=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=C3)[C@H]2O)=N1 DWHYXLJHJYJIMZ-VLIAUNLRSA-N 0.000 description 1
- DWHYXLJHJYJIMZ-VBKZILBWSA-N CN1C=CC(C[C@H]2COC3=C(C=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=C3)[C@@H]2O)=N1 Chemical compound CN1C=CC(C[C@H]2COC3=C(C=CC(C4=C(NS(=O)(=O)C(F)(F)F)C=CC=C4)=C3)[C@@H]2O)=N1 DWHYXLJHJYJIMZ-VBKZILBWSA-N 0.000 description 1
- VRFUNWJFDOEHNA-GDPJSUAHSA-N CN1N=C(C2=CC=CC=C2)C=C1C[C@@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@H]1O.CN1N=C(C2=CC=CC=C2)C=C1C[C@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@@H]1O.CN1N=C(C2=CC=[C+]C=C2)C=C1C[C@@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@H]1O.CN1N=C(C2=CC=[C+]C=C2)C=C1C[C@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@@H]1O Chemical compound CN1N=C(C2=CC=CC=C2)C=C1C[C@@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@H]1O.CN1N=C(C2=CC=CC=C2)C=C1C[C@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@@H]1O.CN1N=C(C2=CC=[C+]C=C2)C=C1C[C@@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@H]1O.CN1N=C(C2=CC=[C+]C=C2)C=C1C[C@H]1COC2=CC(C3=C(NS(C)(=O)=O)C=CC=C3)=CC=C2[C@@H]1O VRFUNWJFDOEHNA-GDPJSUAHSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N CNC(C)=O Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- YYNRTZZKNANZSI-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC3=C(C=C2)C(O)C(CC2=CC=CC=N2)CO3)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC3=C(C=C2)C(O)C(CC2=CC=CC=N2)CO3)C=CC=C1 YYNRTZZKNANZSI-UHFFFAOYSA-N 0.000 description 1
- PPJVPKKNTBLYPF-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(C/C2=C/C4=C(C=CC=C4)S2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(C/C2=C/C4=C(C=CC=C4)S2)C3O)C=CC=C1 PPJVPKKNTBLYPF-UHFFFAOYSA-N 0.000 description 1
- MHZPKFMTVXVWLL-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CS2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CS2)C3O)C=CC=C1 MHZPKFMTVXVWLL-UHFFFAOYSA-N 0.000 description 1
- FWWBCFAFDHWJQQ-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=CC=C2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=CC=C2)C3O)C=CC=C1 FWWBCFAFDHWJQQ-UHFFFAOYSA-N 0.000 description 1
- ZREVWLVYKYJSAA-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=C2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=C2)C3O)C=CC=C1 ZREVWLVYKYJSAA-UHFFFAOYSA-N 0.000 description 1
- ZPGUZYOAIXBYDM-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)C3O)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)C3O)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)C3O)C=CC=C1 ZPGUZYOAIXBYDM-UHFFFAOYSA-N 0.000 description 1
- QTIKSMDIZKZNBG-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=NNC=C2)C3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OCC(CC2=NNC=C2)C3O)C=CC=C1 QTIKSMDIZKZNBG-UHFFFAOYSA-N 0.000 description 1
- YYNRTZZKNANZSI-ZHRRBRCNSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1 YYNRTZZKNANZSI-ZHRRBRCNSA-N 0.000 description 1
- LMDQFMRHJPWYMZ-UZGZRLCMSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=NC=C2)[C@@H]3O)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=NC=C2)[C@H]3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=NC=C2)[C@@H]3O)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=NC=C2)[C@H]3O)C=CC=C1 LMDQFMRHJPWYMZ-UZGZRLCMSA-N 0.000 description 1
- YYNRTZZKNANZSI-KSFYIVLOSA-N CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=C1 YYNRTZZKNANZSI-KSFYIVLOSA-N 0.000 description 1
- KJZVODICYJACLG-YIITUBAUSA-N C[C@@H](C1=CC=CC=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@@H]1O.C[C@@H](C1=CC=CC=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@@H]1O.C[C@H](C1=CC=CC=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.C[C@H](C1=CC=CC=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@@H]1O Chemical compound C[C@@H](C1=CC=CC=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@@H]1O.C[C@@H](C1=CC=CC=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@@H]1O.C[C@H](C1=CC=CC=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@H]1O.C[C@H](C1=CC=CC=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC(F)=C3)=CC=C2[C@@H]1O KJZVODICYJACLG-YIITUBAUSA-N 0.000 description 1
- VCTPNNJJLMMMGZ-ROWZACFDSA-N C[C@@H](C1=CSC(C2=CC=CC=C2)=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O.C[C@H](C1=CSC(C2=CC=CC=C2)=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O.C[C@H](C1=CSC(C2=CC=CC=C2)=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O Chemical compound C[C@@H](C1=CSC(C2=CC=CC=C2)=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O.C[C@H](C1=CSC(C2=CC=CC=C2)=N1)[C@@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@H]1O.C[C@H](C1=CSC(C2=CC=CC=C2)=N1)[C@H]1COC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C2[C@@H]1O VCTPNNJJLMMMGZ-ROWZACFDSA-N 0.000 description 1
- DFGCDVSEQVKGKI-UHFFFAOYSA-N Cc1cnc(CC(COc2cc(-c(cccc3)c3NS(C(F)(F)F)(=O)=O)ccc22)C2O)cc1 Chemical compound Cc1cnc(CC(COc2cc(-c(cccc3)c3NS(C(F)(F)F)(=O)=O)ccc22)C2O)cc1 DFGCDVSEQVKGKI-UHFFFAOYSA-N 0.000 description 1
- ADTZXVKXCVPYOY-UHFFFAOYSA-N O=C1CCOC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C12 Chemical compound O=C1CCOC2=CC(C3=C(NS(=O)(=O)C(F)(F)F)C=CC=C3)=CC=C12 ADTZXVKXCVPYOY-UHFFFAOYSA-N 0.000 description 1
- XTZCAEIXDVYGKR-KSFYIVLOSA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC3=C(C=C2)[C@H](O)[C@@H](CC2=CC=CC=N2)CO3)C=CC=C1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC3=C(C=C2)[C@H](O)[C@@H](CC2=CC=CC=N2)CO3)C=CC=C1 XTZCAEIXDVYGKR-KSFYIVLOSA-N 0.000 description 1
- XPQBZOINJQRJMJ-UHFFFAOYSA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)C=C(F)C=N1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)C=C(F)C=N1 XPQBZOINJQRJMJ-UHFFFAOYSA-N 0.000 description 1
- DHULDOBKQDBJMM-UHFFFAOYSA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)N=C(C(F)(F)F)C=N1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)N=C(C(F)(F)F)C=N1 DHULDOBKQDBJMM-UHFFFAOYSA-N 0.000 description 1
- IFUUIQZUICZAKS-UHFFFAOYSA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)N=CC=N1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)N=CC=N1 IFUUIQZUICZAKS-UHFFFAOYSA-N 0.000 description 1
- XTZCAEIXDVYGKR-ZHRRBRCNSA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1 XTZCAEIXDVYGKR-ZHRRBRCNSA-N 0.000 description 1
- LYVWQGHHMFIWAK-QRWLVFNGSA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=N1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=N1 LYVWQGHHMFIWAK-QRWLVFNGSA-N 0.000 description 1
- LYVWQGHHMFIWAK-MGPUTAFESA-N O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=N1 Chemical compound O=S(=O)(CC(F)(F)F)NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=N1 LYVWQGHHMFIWAK-MGPUTAFESA-N 0.000 description 1
- MSLWPRWIBSIYTG-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC3=C(C=C2)C(O)C(CC2=CC=CC=N2)CO3)C=C(F)C=N1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC3=C(C=C2)C(O)C(CC2=CC=CC=N2)CO3)C=C(F)C=N1)C(F)(F)F MSLWPRWIBSIYTG-UHFFFAOYSA-N 0.000 description 1
- DAUHLVUFIMVAPY-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC3=C(C=C2)C(O)C(CC2=CC=CC=N2)CO3)C=CC=N1)C(F)F Chemical compound O=S(=O)(NC1=C(C2=CC3=C(C=C2)C(O)C(CC2=CC=CC=N2)CO3)C=CC=N1)C(F)F DAUHLVUFIMVAPY-UHFFFAOYSA-N 0.000 description 1
- IWCDTDLEWGZBRX-WOKNPCPGSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)C=C2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)C=C2)[C@@H]3O)C=CC=C1)C(F)(F)F IWCDTDLEWGZBRX-WOKNPCPGSA-N 0.000 description 1
- IWCDTDLEWGZBRX-GBAZGAGXSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)C=C2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)C=C2)[C@H]3O)C=CC=C1)C(F)(F)F IWCDTDLEWGZBRX-GBAZGAGXSA-N 0.000 description 1
- XFXKPTLVSMSIIT-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)S2)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=C(C4=CC=CC=C4)S2)C3O)C=CC=C1)C(F)(F)F XFXKPTLVSMSIIT-UHFFFAOYSA-N 0.000 description 1
- ABZARZCUFIMMNJ-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)C=CC=N1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CC=CC=N2)C3O)C=CC=N1)C(F)(F)F ABZARZCUFIMMNJ-UHFFFAOYSA-N 0.000 description 1
- GAJZEODSTKDFQN-UCSBTNPJSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN(C4=CC=CC=C4)N=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN(C4=CC=CC=C4)N=N2)[C@@H]3O)C=CC=C1)C(F)(F)F GAJZEODSTKDFQN-UCSBTNPJSA-N 0.000 description 1
- RKQFOZDZWOAFRX-LUTIACGYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=C(C4=CC=CC=C4)S2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=C(C4=CC=CC=C4)S2)[C@@H]3O)C=CC=C1)C(F)(F)F RKQFOZDZWOAFRX-LUTIACGYSA-N 0.000 description 1
- RKQFOZDZWOAFRX-VCUSLETLSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=C(C4=CC=CC=C4)S2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=C(C4=CC=CC=C4)S2)[C@H]3O)C=CC=C1)C(F)(F)F RKQFOZDZWOAFRX-VCUSLETLSA-N 0.000 description 1
- PJGYVKPMTGYAOX-LGTGAQBVSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=CC=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CN=CC=N2)[C@@H]3O)C=CC=C1)C(F)(F)F PJGYVKPMTGYAOX-LGTGAQBVSA-N 0.000 description 1
- YQKPODLFLXGQQG-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CNN=C2)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CNN=C2)C3O)C=CC=C1)C(F)(F)F YQKPODLFLXGQQG-UHFFFAOYSA-N 0.000 description 1
- KRJVVXCIGHOSJJ-YFKXAPIDSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)[C@@H]3O)C=CC=C1)C(F)(F)F KRJVVXCIGHOSJJ-YFKXAPIDSA-N 0.000 description 1
- KRJVVXCIGHOSJJ-GAGCMDECSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=CSC=N2)[C@H]3O)C=CC=C1)C(F)(F)F KRJVVXCIGHOSJJ-GAGCMDECSA-N 0.000 description 1
- SCRJJQSBOCJOKU-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NC=CC=C2F)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NC=CC=C2F)C3O)C=CC=C1)C(F)(F)F SCRJJQSBOCJOKU-UHFFFAOYSA-N 0.000 description 1
- BNNXWOFRROMHTP-YFKXAPIDSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NC=CO2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NC=CO2)[C@@H]3O)C=CC=C1)C(F)(F)F BNNXWOFRROMHTP-YFKXAPIDSA-N 0.000 description 1
- NTJWHQHBUNSQIA-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NN=C(C4=CC=C(F)C=C4)O2)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NN=C(C4=CC=C(F)C=C4)O2)C3O)C=CC=C1)C(F)(F)F NTJWHQHBUNSQIA-UHFFFAOYSA-N 0.000 description 1
- XJWGNJYSTSSPEX-UHFFFAOYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NNC=C2)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OCC(CC2=NNC=C2)C3O)C=CC=C1)C(F)(F)F XJWGNJYSTSSPEX-UHFFFAOYSA-N 0.000 description 1
- ZWQPQXVTDNQVQI-VGSWGCGISA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=C2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=C2)[C@@H]3O)C=CC=C1)C(F)(F)F ZWQPQXVTDNQVQI-VGSWGCGISA-N 0.000 description 1
- KGVYIOCRULZFBE-XIKOKIGWSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=C(Cl)N=N1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=C(Cl)N=N1)C(F)(F)F KGVYIOCRULZFBE-XIKOKIGWSA-N 0.000 description 1
- LQJGUIHCBZHGCL-VFNWGFHPSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1)C(F)(F)F LQJGUIHCBZHGCL-VFNWGFHPSA-N 0.000 description 1
- XSZKNZCUKGBPNH-VFNWGFHPSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1)C(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CC=N2)[C@@H]3O)C=CC=C1)C(F)F XSZKNZCUKGBPNH-VFNWGFHPSA-N 0.000 description 1
- NJGYZPXYDIXYFF-VLIAUNLRSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CN=N2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CN=N2)[C@@H]3O)C=CC=C1)C(F)(F)F NJGYZPXYDIXYFF-VLIAUNLRSA-N 0.000 description 1
- OQSRFWLTERBAMO-VLIAUNLRSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CS2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=CS2)[C@@H]3O)C=CC=C1)C(F)(F)F OQSRFWLTERBAMO-VLIAUNLRSA-N 0.000 description 1
- VRLGCEYGZLUKFW-CJAUYULYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=NN2C2=CC=CC=C2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CC=NN2C2=CC=CC=C2)[C@@H]3O)C=CC=C1)C(F)(F)F VRLGCEYGZLUKFW-CJAUYULYSA-N 0.000 description 1
- RKQFOZDZWOAFRX-KOSHJBKYSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CN=C(C4=CC=CC=C4)S2)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=CN=C(C4=CC=CC=C4)S2)[C@@H]3O)C=CC=C1)C(F)(F)F RKQFOZDZWOAFRX-KOSHJBKYSA-N 0.000 description 1
- SCRJJQSBOCJOKU-SZNDQCEHSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=NC=CC=C2F)[C@@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@@H](CC2=NC=CC=C2F)[C@@H]3O)C=CC=C1)C(F)(F)F SCRJJQSBOCJOKU-SZNDQCEHSA-N 0.000 description 1
- ZWQPQXVTDNQVQI-HTAPYJJXSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=C2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=C2)[C@H]3O)C=CC=C1)C(F)(F)F ZWQPQXVTDNQVQI-HTAPYJJXSA-N 0.000 description 1
- LQJGUIHCBZHGCL-YCRPNKLZSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=C1)C(F)(F)F LQJGUIHCBZHGCL-YCRPNKLZSA-N 0.000 description 1
- XSZKNZCUKGBPNH-YCRPNKLZSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=C1)C(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CC=N2)[C@H]3O)C=CC=C1)C(F)F XSZKNZCUKGBPNH-YCRPNKLZSA-N 0.000 description 1
- NJGYZPXYDIXYFF-VBKZILBWSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CN=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CN=N2)[C@H]3O)C=CC=C1)C(F)(F)F NJGYZPXYDIXYFF-VBKZILBWSA-N 0.000 description 1
- OQSRFWLTERBAMO-VBKZILBWSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CS2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=CS2)[C@H]3O)C=CC=C1)C(F)(F)F OQSRFWLTERBAMO-VBKZILBWSA-N 0.000 description 1
- VRLGCEYGZLUKFW-AVRWGWEMSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=NN2C2=CC=CC=C2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CC=NN2C2=CC=CC=C2)[C@H]3O)C=CC=C1)C(F)(F)F VRLGCEYGZLUKFW-AVRWGWEMSA-N 0.000 description 1
- PJGYVKPMTGYAOX-VBKZILBWSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CN=CC=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CN=CC=N2)[C@H]3O)C=CC=C1)C(F)(F)F PJGYVKPMTGYAOX-VBKZILBWSA-N 0.000 description 1
- ZTWUHDQWQOWCFB-YCRPNKLZSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CSC(C4CC4)=N2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=CSC(C4CC4)=N2)[C@H]3O)C=CC=C1)C(F)(F)F ZTWUHDQWQOWCFB-YCRPNKLZSA-N 0.000 description 1
- SCRJJQSBOCJOKU-LHSJRXKWSA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=NC=CC=C2F)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=NC=CC=C2F)[C@H]3O)C=CC=C1)C(F)(F)F SCRJJQSBOCJOKU-LHSJRXKWSA-N 0.000 description 1
- BNNXWOFRROMHTP-ORAYPTAESA-N O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=NC=CO2)[C@H]3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=C(C2=CC=C3C(=C2)OC[C@H](CC2=NC=CO2)[C@H]3O)C=CC=C1)C(F)(F)F BNNXWOFRROMHTP-ORAYPTAESA-N 0.000 description 1
- DZQVDRYSLJVKAO-UHFFFAOYSA-N O=S(=O)(NC1=CC=C(F)C=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=N1)C2O)C(F)(F)F Chemical compound O=S(=O)(NC1=CC=C(F)C=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=N1)C2O)C(F)(F)F DZQVDRYSLJVKAO-UHFFFAOYSA-N 0.000 description 1
- QXIPZSYAMOYXHO-UHFFFAOYSA-N O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)C(O)C(CC1=CC=CC=C1)CO2)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)C(O)C(CC1=CC=CC=C1)CO2)C(F)(F)F Chemical compound O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)C(O)C(CC1=CC=CC=C1)CO2)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)C(O)C(CC1=CC=CC=C1)CO2)C(F)(F)F QXIPZSYAMOYXHO-UHFFFAOYSA-N 0.000 description 1
- QRWHQIIQBIDPQZ-LHSJRXKWSA-N O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)[C@H](O)[C@@H](CC1=CC=C(F)C=N1)CO2)C(F)(F)F Chemical compound O=S(=O)(NC1=CC=CC=C1C1=CC2=C(C=C1)[C@H](O)[C@@H](CC1=CC=C(F)C=N1)CO2)C(F)(F)F QRWHQIIQBIDPQZ-LHSJRXKWSA-N 0.000 description 1
- WKHDATKEXOJBQH-UHFFFAOYSA-N O=S(=O)(NC1=NC=CN=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=N1)C2O)C(F)(F)F Chemical compound O=S(=O)(NC1=NC=CN=C1C1=CC=C2C(=C1)OCC(CC1=CC=CC=N1)C2O)C(F)(F)F WKHDATKEXOJBQH-UHFFFAOYSA-N 0.000 description 1
- ICMKRHXEGDLPPS-UHFFFAOYSA-N O=S(=O)([N-]C1=C(C2=CC=C3C(=C2)OCC(CC2=CC=NN2C2=CC=CC=C2)C3O)C=CC=C1)C(F)(F)F Chemical compound O=S(=O)([N-]C1=C(C2=CC=C3C(=C2)OCC(CC2=CC=NN2C2=CC=CC=C2)C3O)C=CC=C1)C(F)(F)F ICMKRHXEGDLPPS-UHFFFAOYSA-N 0.000 description 1
- IWCDTDLEWGZBRX-NEKDWFFYSA-N O[C@H]([C@@H](Cc(cc1)ccc1-c1ccccc1)COc1c2)c1ccc2-c(cccc1)c1NS(C(F)(F)F)(=O)=O Chemical compound O[C@H]([C@@H](Cc(cc1)ccc1-c1ccccc1)COc1c2)c1ccc2-c(cccc1)c1NS(C(F)(F)F)(=O)=O IWCDTDLEWGZBRX-NEKDWFFYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- Diabetes mellitus is a disease derived from multiple causative factors and characterized by elevated levels of plasma glucose (hyperglycemia) in the fasting state or after administration of glucose during an oral glucose tolerance test.
- diabetes There are two generally recognized forms of diabetes.
- IDDM insulin-dependent diabetes mellitus
- IDDM insulin-dependent diabetes mellitus
- NIDDM noninsulin-dependent diabetes mellitus
- insulin is still produced in the body, however patients have a resistance to the effects of insulin in stimulating glucose and lipid metabolism in the insulin-sensitive tissues such as muscle, liver and adipose.
- Persistent or uncontrolled hyperglycemia is associated with increased and premature morbidity and mortality. Impaired glucose homeostasis is associated both directly and indirectly with obesity, hypertension, and alterations of the lipid, lipoprotein and apolipoprotein metabolism, as well as other metabolic and hemodynamic diseases. Patients with Type 2 diabetes mellitus have a significantly increased risk of macrovascular and microvascular complications, including atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, hypertension, nephropathy, neuropathy, and retinopathy. Therefore, therapeutic control of glucose homeostasis, lipid metabolism, obesity, and hypertension are critically important in the clinical management and treatment of diabetes mellitus.
- hepatic glucose production biguanides, such as phenformin and metformin
- insulin resistance PPAR agonists, such as rosiglitazone, troglitazone, engliazone, balaglitazone, and pioglitazone
- insulin secretion sulfonylureas, such as tolbutamide, glipizide and glimipiride
- incretin hormone mimetics GLP-1 derivatives and analogs, such as exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide, albiglutide and taspoglutide
- DPP-4 inhibitors such as sitagliptin, alogliptin, vildagliptin, linagliptin, denagliptin and saxagliptin).
- PPAR gamma agonists such as rosiglitazone and pioglitazone
- rosiglitazone and pioglitazone are modestly effective in reducing plasma glucose and hemoglobin A1C.
- the currently marketed glitazones do not greatly improve lipid metabolism and may negatively effect on the lipid profile.
- insulin secretagogues such as the sulfonylureas (e.g. tolbutamide, glipizide, and glimepiride) can result in hypoglycemia; their administration must therefore be carefully controlled.
- Leukotriene B 4 is a pro-inflammatory lipid mediator generated from arachidonic acid through the activities of 5-lipoxygenase, 5-lipoxygenase activating protein (FLAP) and leukotriene A4 hydrolase (LTA4H) (Samuelsson et al., Science 1987; 237:1171-1176, Haeggstrom, J Z, J. Biol Chem. 2004; 279:50639-50642).
- LTB 4 is a chemoattractant and regulates the proinflammatory cytokines by binding to a G-protein coupled receptor leukotriene B 4 receptor 1 (BLT1) and leukotriene B 4 receptor 2 (BLT2).
- BLT1 G-protein coupled receptor leukotriene B 4 receptor 1
- BLT2 leukotriene B 4 receptor 2
- LTB 4 has been considered an endogenous mediator for the recruitment of inflammatory cells in acute and chronic disease states and has been associated with inflamed tissue in rheumatoid arthritis, psoriasis, inflammatory bowel disease and asthmas; and LTB 4 receptor antagonists were developed for the treatment of variety of inflammatory diseases (Dalvie et al., Xenobiotica, 1999, Vol. 29, No. 11, 11-23-1140).
- LTB 4 :BLT1 plays an important role in host defense during acute infection. Choronic activation of the LTB 4 :BLT1 pathway contributes to the development of inflammatory diseases such as atherosclerosis and arthritis. BLT1, a high affinity receptor specific for LTB 4 , is demonstrated to express predominantly in leucocytes. BLT2, a low affinity receptor for LTB 4 , is ubiquitiously expressed.
- BLT1 and dual BLT1/BLT2 antagonists were pursued for treating inflammatory conditions including asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, cystic fibrosis, rheumatic arthritis and cancer.
- Recent publications suggest a potential BLT1 involvement in mediating tumor progression and the blockade of LTB 4 /BLT1 pathways could generate benefits in controlling tumor growth (Yokota et al., Blood, 2012; 120:3444-3454; Woo-Kwang Jeon et al., The proinflammatory LTB 4 /BLT1 signal axis confers resistance to TGF- ⁇ 1-induced growth inhibition by targeting Smad3 linker region, Oncotarget, Advance Publications 2015; and Wang, Luman et al., Am J Respir Crit Care Med 2012, 186: 989-998).
- BLT1 deficiency of BLT1 protects against the development of insulin resistance in diet-induced obesity by regulating adipose tissue macrophage accumulation and inflammation in insulin-sensitive tissues.
- the study also found that 1) BLT1 deficiency improves glucose and insulin-tolerance in diet induced obese mouse model; 2) BLT1 is a key regulator of macrophage accumulation in adipose tissue and systemic insulin signaling; and 3) the BLT1 pathway points towards new avenues for the therapeutic management of obesity and type 2 diabetes (Spite et al., J Immunol., 2011, 15, 187(4), 1942-1949).
- BLT1 leukotriene B 4 receptor 1
- Leukotriene B 4 (LTB 4 ) receptor antagonists are disclosed in: WO 93/015066; WO 93/015067; WO 96/006604; WO 96/011920; WO 96/011925; WO 96/41645; WO 98/011119; WO 03/007947; WO 13/106238; U.S. Pat. Nos. 5,550,152; 5,552,435; 5,939,452; 6,051,601; 6,117,874; 6,133,286; US 2009/054466; US 2009/253684; US 2009/227603; EP00518819; Koch et al., J. Med. Chem., 1994, Vol. 37, No.
- Hydroxy tetralins are disclosed in U.S. Pat. Nos. 5,215,989; 5,032,598; and EP 0 431 945.
- the present invention relates to novel substituted compounds of structural formula I:
- the compounds of structural formula I, and embodiments thereof, are antagonists of leukotriene B 4 receptor 1 (BLT1 antagonists) and may be useful in the treatment, prevention and suppression of diseases, disorders and conditions mediated by antagonism of the BLT1 receptor, such as Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
- BLT1 antagonists leukotriene B 4 receptor 1
- the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
- the present invention also relates to methods for the treatment, control or prevention of disorders, diseases, and conditions that may be responsive to antagonism of the BLT1 receptor in a subject in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
- the present invention also relates to the use of compounds of the present invention for manufacture of a medicament useful in treating diseases, disorders and conditions that may be responsive to the antagonism of the BLT1 receptor.
- the present invention is also concerned with treatment of these diseases, disorders and conditions by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent that may be useful to treat the disease, disorder and condition.
- the invention is further concerned with processes for preparing the compounds of this invention.
- the present invention is concerned with novel compounds of structural Formula I:
- A is selected from the group consisting of:
- aryl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen;
- B is selected from the group consisting of:
- aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen and CF 3 , and wherein heteroaryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 ;
- X is selected from the group consisting of:
- alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl;
- Z is selected from the group consisting of:
- R a is selected from the group consisting of:
- R b is selected from the group consisting of:
- the invention has numerous embodiments, which are summarized below.
- the invention includes the compounds as shown, and also includes individual diastereoisomers, enantiomers, and epimers of the compounds, and mixtures of diastereoisomers and/or enantiomers thereof including racemic mixtures.
- A is selected from the group consisting of: aryl, and heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: aryl, and heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: aryl and heteroaryl.
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from: C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from cyclopropyl, CH 3 and F.
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from cyclopropyl.
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from CH 3 .
- A is selected from the group consisting of: phenyl, and heteroaryl, wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from F.
- A is selected from the group consisting of: phenyl, pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein phenyl, pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: phenyl, pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein phenyl, pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-4 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: phenyl, pyrazole, pyridine, thiophene, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: phenyl, pyrazole, pyridine, thiophene, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from cyclopropyl, CH 3 and F.
- A is selected from the group consisting of: phenyl, pyrazole, pyridine, thiophene, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from cyclopropyl, CH 3 and F.
- A is selected from the group consisting of: phenyl, pyrazole, pyridine, thiophene, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 and F.
- A is selected from the group consisting of: phenyl, pyridine, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and halogen.
- A is selected from the group consisting of phenyl, pyridine, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from cyclopropyl, CH 3 and F.
- A is selected from the group consisting of phenyl, pyridine, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 and F.
- A is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl and halogen. In another embodiment, A is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and halogen. In another embodiment, A is aryl.
- A is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl and halogen. In another embodiment, A is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and halogen. In another embodiment, A is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 and F. In another embodiment, A is phenyl.
- A is heteroaryl, wherein heteroaryl is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen. In another embodiment, A is heteroaryl, wherein heteroaryl is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, and halogen. In another embodiment, A is heteroaryl.
- A is selected from the group consisting of pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: pyrazole, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein pyrazole, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: pyrazole, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein pyrazole, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen.
- A is selected from the group consisting of: thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine, wherein thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from: cyclopropyl, CH 3 , CH 2 CH 3 , —C(CH 3 ) 3 , and F.
- A is selected from the group consisting of: pyrazole, pyridine, thiophene, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- A is selected from the group consisting of: pyrazole, pyridine, thiophene, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from CH 3 and F.
- A is selected from the group consisting of: pyrazole, pyridine, thiophene, thiazole, and benzothiophene.
- A is selected from the group consisting of: pyrazole, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- A is selected from the group consisting of: pyrazole, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from CH 3 and F.
- A is selected from the group consisting of: pyrazole, thiazole, and benzothiophene.
- A is selected from the group consisting of: pyridine, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- A is selected from the group consisting of: pyridine, thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from CH 3 and F.
- A is selected from the group consisting of: pyridine, thiazole, and benzothiophene.
- A is selected from the group consisting of: thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- A is selected from the group consisting of: thiazole, and benzothiophene, wherein A is unsubstituted or substituted with 1-3 substituents independently selected from CH 3 and F.
- A is selected from the group consisting of: thiazole, and benzothiophene.
- A is pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen. In another embodiment, A is pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from CH 3 and F. In another embodiment, A is pyridine.
- A is selected from the group consisting of: pyrazole, and pyridine, wherein pyrazole and pyridine are independently unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- A is selected from the group consisting of: pyrazole and pyridine.
- A is pyrazole.
- A is pyridine.
- B is selected from the group consisting of: aryl, and heteroaryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen and CF 3 , and wherein heteroaryl is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 .
- B is selected from the group consisting of: aryl, and heteroaryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, and wherein heteroaryl is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- B is selected from the group consisting of: phenyl, pyrazine, pyridine, and pyridazine, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen and CF 3 , and wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 .
- B is selected from the group consisting of: phenyl, pyrazine, pyridine, and pyridazine, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, F, Cl, and CF 3 , and wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, F, Cl, and CF 3 .
- B is selected from the group consisting of: phenyl, and pyridine, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, and wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- B is selected from the group consisting of: phenyl, pyrazine, pyridine, and pyridazine, wherein phenyl is unsubstituted, and wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 .
- B is selected from the group consisting of: phenyl, pyrazine, pyridine, and pyridazine, wherein phenyl is unsubstituted, and wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, F, Cl, and CF 3 .
- B is selected from the group consisting of: phenyl, pyrazine, pyridine, and pyridazine, wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 .
- B is selected from the group consisting of: phenyl, pyrazine, pyridine, and pyridazine, wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, F, Cl, and CF 3
- B is selected from the group consisting of: phenyl, and pyridine, wherein phenyl is unsubstituted, and wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and halogen.
- B is selected from the group consisting of: phenyl, and pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from halogen.
- B is selected from the group consisting of: phenyl, and pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl and F.
- B is selected from the group consisting of: phenyl, and pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from F.
- B is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and halogen. In another embodiment of the present invention, B is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and F. In another embodiment of the present invention, B is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl. In another embodiment of the present invention, B is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 .
- B is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from halogen. In another embodiment of the present invention, B is aryl, wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from F. In another embodiment of the present invention, B is aryl.
- B is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and halogen. In another embodiment of the present invention, B is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl and F. In another embodiment of the present invention, B is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl. In another embodiment of the present invention, B is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 .
- B is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from halogen. In another embodiment of the present invention, B is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from F. In another embodiment of the present invention, B is phenyl.
- B is heteroaryl, wherein heteroaryl is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen and CF 3 .
- B is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one substituent selected from C 1-6 alkyl, halogen and CF 3 .
- B is pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen and CF 3 .
- B is pyridine, wherein pyridine is unsubstituted or substituted with one substituent selected from C 1-6 alkyl, halogen and CF 3 .
- B is pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from halogen. In another embodiment of the present invention, B is pyridine, wherein pyridine is unsubstituted or substituted with one substituent selected from halogen. In another embodiment of the present invention, B is pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from F. In another embodiment of the present invention, B is pyridine, wherein pyridine is unsubstituted or substituted with one substituent selected from F.
- B is pyrazine, wherein pyrazine is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen and CF 3 .
- B is pyrazine, wherein pyrazine is unsubstituted or substituted with one substituent selected from C 1-6 alkyl, halogen and CF 3 .
- X is selected from the group consisting of: —NHSO 2 CF 3 , —NHSO 2 CH 2 CF 3 , —NHSO 2 CHF 2 , —NHSO 2 C 1-6 alkyl, and —NHSO 2 C 3-6 cycloalkyl, wherein alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl.
- X is selected from the group consisting of: —NHSO 2 CF 3 , —NHSO 2 CH 2 CF 3 , —NHSO 2 CHF 2 , —NHSO 2 CH 3 , and NHSO 2 -cyclopropyl, wherein cyclopropyl are unsubstituted or substituted with 1-3 substituents independently selected from CH 3 .
- X is selected from the group consisting of: —NHSO 2 CF 3 , —NHSO 2 CH 2 CF 3 , —NHSO 2 C 1-4 alkyl, and —NHSO 2 CHF 2 .
- X is selected from the group consisting of: —NHSO 2 CF 3 , —NHSO 2 CH 2 CF 3 , —NHSO 2 CH 3 , and —NHSO 2 CHF 2 .
- X is selected from the group consisting of: —NHSO 2 CF 3 , —NHSO 2 CH 2 CF 3 , and —NHSO 2 CHF 2 . In another embodiment of the present invention, X is —NHSO 2 CF 3 .
- X is selected from the group consisting of: —NHSO 2 CH 2 CF 3 , —NHSO 2 C 2-4 alkyl, and —NHSO 2 CHF 2 .
- X is selected from the group consisting of: —NHSO 2 CH 2 CF 3 , and —NHSO 2 C 2-4 alkyl.
- Z is selected from the group consisting of: hydrogen, —C 1-6 alkyl, and phenyl, wherein alkyl and phenyl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl.
- Z is selected from the group consisting of: hydrogen, and phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 .
- Z is selected from the group consisting of: hydrogen, and phenyl, wherein phenyl is unsubstituted or substituted with one substituent selected from CH 3 .
- Z is selected from the group consisting of: hydrogen, and phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl. In another embodiment of the present invention, Z is selected from the group consisting of: hydrogen, and phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 .
- Z is C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl.
- Z is hydrogen
- Z is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl. In another embodiment of the present invention, Z is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from CH 3 .
- R a is selected from the group consisting of: hydrogen, and C 1-6 alkyl. In another embodiment of the present invention, R a is selected from the group consisting of: hydrogen, and CH 3 . In another embodiment of the present invention, R a is hydrogen. In another embodiment of the present invention, R a is CH 3 .
- R b is selected from the group consisting of: hydrogen, and C 1-6 alkyl. In another embodiment of the present invention, R b is selected from the group consisting of: hydrogen, and CH 3 . In another embodiment of the present invention, R b is hydrogen. In another embodiment of the present invention, R b is CH 3 .
- the invention relates to compounds of structural formula Ia:
- the invention relates to compounds of structural formula Ib:
- the invention relates to compounds of structural formula Ic:
- the invention relates to compounds of structural formula Id:
- the invention relates to compounds of structural formula Ie:
- the invention relates to compounds of structural formula If:
- the invention relates to compounds of structural formula Ig:
- the invention relates to compounds of structural formula Ig wherein the * bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Ih:
- the invention relates to compounds of structural formula Ih wherein the * bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Ii:
- the invention relates to compounds of structural formula Ii wherein the bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Ij:
- the invention relates to compounds of structural formula Ij wherein the * bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Ik:
- the invention relates to compounds of structural formula Ik wherein the * bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Il:
- the invention relates to compounds of structural formula Il wherein the * bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Im:
- the invention relates to compounds of structural formula Im wherein the * bonds are cis bonds, or a pharmaceutically acceptable salt thereof.
- the compounds of structural formula I have the following trans bond configuration:
- the compound of structural formula I has the following trans bond configuration:
- bonds refers to bonds with the following stereochemistry:
- the compounds of structural formula I have the following cis bond configuration:
- the compound of structural formula I has the following cis bond configuration:
- the compound of structural formula I includes the compounds of structural formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, Im, In, Io, Ip, and Iq, and pharmaceutically acceptable salts, hydrates and solvates thereof.
- A is selected from the group consisting of:
- phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen;
- B is selected from the group consisting of:
- pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 ;
- X is selected from the group consisting of
- alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl;
- Z is selected from the group consisting of
- alkyl and phenyl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl; and R a and R b are independently selected from the group consisting of: hydrogen, and C 1-6 alkyl; or a pharmaceutically acceptable salt thereof.
- A is heteroaryl; B is phenyl; X is —NHSO 2 CF 3 ; Z is hydrogen; and R a and R b are hydrogen; or a pharmaceutically acceptable salt thereof.
- Illustrative, but non-limiting, examples of the compounds of the present invention that are useful as antagonists of the leukotriene B 4 receptor 1 (BLT1) are the following compounds:
- stereoisomers including diastereoisomers, enantiomers, epimers, and mixtures of these may also have utility in treating BLT1 mediated diseases.
- Alkyl means saturated carbon chains which may be linear or branched or combinations thereof, unless the carbon chain is defined otherwise.
- the term —C 2 alkyl is ethyl. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. In one embodiment of the present invention, alkyl is methyl.
- Cycloalkyl means a saturated monocyclic, bicyclic or bridged carbocyclic ring, having a specified number of carbon atoms.
- Examples of cycloalkyl include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. In one embodiment of the present invention, cycloalkyl is cyclopropyl.
- Aryl means a monocyclic or bicyclic carbocyclic aromatic ring or ring system containing 5-14 carbon atoms, wherein at least one of the rings is aromatic.
- aryl include phenyl and naphthyl. In one embodiment of the present invention, aryl is phenyl.
- Heteroaryl means monocyclic, or bicyclic ring or ring system containing 3-14 carbon atoms and containing at least one ring heteroatom selected from N, NH, S (including SO and SO 2 ) and O, wherein at least one of the heteroatom containing rings is aromatic.
- heteroaryl include pyrazole, pyridine, thiophene, thiazole and benzothiophene.
- heteroaryl is pyrazole, pyridine, thiophene, thiazole and benzothiophene.
- heteroaryl is pyridine.
- heteroaryl is pyrazole, and pyridine.
- heteroaryl is thiazole
- heteroaryl is pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine.
- heteroaryl is pyrazine, pyridine, and pyridazine.
- Halogen includes fluorine, chlorine, bromine and iodine. In one embodiment of the present invention, halogen is bromine, chlorine or fluorine. In another embodiment of the present invention, halogen is chlorine or fluorine. In another embodiment of the present invention, halogen is bromine. In another embodiment of the present invention, halogen is chlorine. In another embodiment of the present invention, halogen is fluorine.
- any variable e.g., R 1 , R a , etc.
- its definition on each occurrence is independent of its definition at every other occurrence.
- combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- a squiggly line across a bond in a substituent variable represents the point of attachment.
- substituents depicted in a structural formula with a “floating” bond such as but not limited to Z, are permitted on any available carbon atom in the ring to which the substituent is attached.
- Z may be substituted on any CH in the ring to which Z is attached.
- substituted shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, salts and/or dosage forms which are, using sound medical judgment, and following all applicable government regulations, safe and suitable for administration to a human being or an animal.
- % enantiomeric excess (abbreviated “ee”) shall mean the % major enantiomer less the % minor enantiomer. Thus, a 70% enantiomeric excess corresponds to formation of 85% of one enantiomer and 15% of the other.
- enantiomeric excess is synonymous with the term “optical purity.”
- Compounds of Formula I may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of Formula I.
- the present invention encompasses all stereoisomeric forms of the compounds of Formula I. Unless a specific stereochemistry is indicated, the present invention is meant to comprehend all such isomeric forms of these compounds. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have (R) configuration or (S) configuration. When bonds to the chiral carbon are depicted as straight lines in the structural Formulas of the invention, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the Formula.
- the invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
- enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
- the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios.
- the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis.
- a derivatization can be carried out before a separation of stereoisomers.
- the separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or it can be done on a final racemic product.
- Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration.
- Tautomers are defined as compounds that undergo rapid proton shifts from one atom of the compound to another atom of the compound. Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of Formula I.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of structural formula I.
- different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H), and tritium ( 3 H).
- Protium is the predominant hydrogen isotope found in nature.
- Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Tritium is radioactive and may therefore provide for a radiolabeled compound, useful as a tracer in metabolic or kinetic studies.
- Isotopically-enriched compounds within structural formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
- the separation can be carried out by methods well-known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereoisomeric mixture, followed by separation of the individual diastereoisomers by standard methods, such as fractional crystallization or chromatography.
- the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
- the diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
- the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
- any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
- crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention.
- some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.
- Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
- references to the compounds of the present invention are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
- the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt,
- suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- basic ion-exchange resins such as arginine, betaine, caffeine, cho
- esters of carboxylic acid derivatives such as methyl, ethyl, or pivaloyloxymethyl
- acyl derivatives of alcohols such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl
- esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
- Solvates, and in particular, the hydrates of the compounds of the present invention are included in the present invention as well.
- the compounds of the present invention are potent antagonists of the leukotriene B 4 receptor 1 (BLT1) receptor.
- BLT1 leukotriene B 4 receptor 1
- the compounds, and pharmaceutically acceptable salts thereof, may be efficacious in the treatment of diseases that are modulated by BLT1 ligands. Many of these diseases are summarized below.
- One or more of these diseases may be treated by the administration of a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, to a patient in need of treatment.
- the compounds of the present invention may be used for the manufacture of a medicament which may be useful for treating one or more of these diseases: (1) non-insulin dependent diabetes mellitus (Type 2 diabetes); (2) obesity; (3) hypertension; (4) dyslipidemia and lipid disorders; (5) cancer; (6) Metabolic Syndrome; (7) myocardial infarction; (8) stroke; (9) insulin resistance; (10) hyperglycemia; (11) Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis; and (12) atherosclerosis.
- Preferred uses of the compounds may be for the treatment of one or more of the following diseases by administering a therapeutically effective amount to a patient in need of treatment.
- the compounds may be used for manufacturing a medicament for the treatment of one or more of these diseases: (1) Type 2 diabetes, and specifically hyperglycemia associated with Type 2 diabetes; (2) Metabolic Syndrome; (3) obesity; and (4) hypercholesterolemia.
- the compounds may be effective in lowering glucose and lipids in diabetic patients and in non-diabetic patients who have impaired glucose tolerance and/or are in a pre-diabetic condition.
- the compounds may ameliorate hyperinsulinemia, which often occurs in diabetic or pre-diabetic patients, by modulating the swings in the level of serum glucose that often occurs in these patients.
- the compounds may also be effective in treating or reducing insulin resistance.
- the compounds may be effective in treating or preventing gestational diabetes.
- the compounds may also be effective in treating or preventing lipid disorders.
- the compounds may be effective in treating or preventing diabetes related disorders.
- the compounds may also be effective in treating or preventing obesity related disorders.
- the invention also includes pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier.
- the compounds may be useful in treating insulin resistance, Type 2 diabetes, hyperglycemia, and dyslipidemia that is associated with Type 2 diabetes and insulin resistance.
- the compounds may also be useful for the treatment of obesity
- a compound of the present invention, or a pharmaceutically acceptable salt thereof, may be used in the manufacture of a medicament for the treatment of Type 2 diabetes in a human or other mammalian patient.
- a method of treating Type 2 diabetes comprises the administration of a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, to a human or other mammalian subject or patient in need of treatment.
- a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound, to a human or other mammalian subject or patient in need of treatment.
- Other medical uses of the compounds of the present invention are described herein.
- diabetes includes both insulin-dependent diabetes mellitus (i.e., IDDM, also known as type 1 diabetes) and non-insulin-dependent diabetes mellitus (i.e., NIDDM, also known as Type 2 diabetes).
- IDDM insulin-dependent diabetes mellitus
- NIDDM non-insulin-dependent diabetes mellitus
- Type 1 diabetes or insulin-dependent diabetes
- Type 2 diabetes or insulin-independent diabetes (i.e., non-insulin-dependent diabetes mellitus)
- Most of the Type 2 diabetics are also obese.
- the compositions of the present invention may be useful for treating both Type 1 and Type 2 diabetes.
- the term “diabetes associated with obesity” refers to diabetes caused by obesity or resulting from obesity.
- Diabetes is characterized by a fasting plasma glucose level of greater than or equal to 126 mg/dl.
- a diabetic subject has a fasting plasma glucose level of greater than or equal to 126 mg/dl.
- a pre diabetic subject is someone suffering from prediabetes.
- Prediabetes is characterized by an impaired fasting plasma glucose (FPG) level of greater than or equal to 110 mg/dl and less than 126 mg/dl; or impaired glucose tolerance; or insulin resistance.
- FPG impaired fasting plasma glucose
- a prediabetic subject is a subject with impaired fasting glucose (a fasting plasma glucose (FPG) level of greater than or equal to 110 mg/dl and less than 126 mg/dl); or impaired glucose tolerance (a 2 hour plasma glucose level of >140 mg/dl and ⁇ 200 mg/dl); or insulin resistance, resulting in an increased risk of developing diabetes.
- FPG fasting plasma glucose
- Treatment of diabetes mellitus refers to the administration of a compound or combination of the present invention to treat a diabetic subject.
- One outcome of treatment may be decreasing the glucose level in a subject with elevated glucose levels.
- Another outcome of treatment may be decreasing insulin levels in a subject with elevated insulin levels.
- Another outcome of treatment may be decreasing plasma triglycerides in a subject with elevated plasma triglycerides.
- Another outcome of treatment is decreasing LDL cholesterol in a subject with high LDL cholesterol levels.
- Another outcome of treatment may be increasing HDL cholesterol in a subject with low HDL cholesterol levels.
- Another outcome of treatment is increasing insulin sensivity.
- Another outcome of treatment may be enhancing glucose tolerance in a subject with glucose intolerance.
- Yet another outcome of treatment may be decreasing insulin resistance in a subject with increased insulin resistance or elevated levels of insulin.
- Prevention of diabetes mellitus refers to the administration of a compound or combination of the present invention to prevent the onset of diabetes in a subject in need thereof.
- a subject in need of preventing diabetes is a prediabetic subject that is overweight or obese.
- diabetes related disorders should be understood to mean disorders that are associated with, caused by, or result from diabetes. Examples of diabetes related disorders include retinal damage, kidney disease, and nerve damage.
- Atherosclerosis encompasses vascular diseases and conditions that are recognized and understood by physicians practicing in the relevant fields of medicine.
- Atherosclerotic cardiovascular disease, coronary heart disease (also known as coronary artery disease or ischemic heart disease), cerebrovascular disease and peripheral vessel disease are all clinical manifestations of atherosclerosis and are therefore encompassed by the terms “atherosclerosis” and “atherosclerotic disease.”
- the combination comprised of a therapeutically effective amount of a BLT1 antagonist in combination with a therapeutically effective amount of an anti-hypertensive agent may be administered to prevent or reduce the risk of occurrence, or recurrence where the potential exists, of a coronary heart disease event, a cerebrovascular event, or intermittent claudication.
- Coronary heart disease events are intended to include CHD death, myocardial infarction (i.e., a heart attack), and coronary revascularization procedures. Cerebrovascular events are intended to include ischemic or hemorrhagic stroke (also known as cerebrovascular accidents) and transient ischemic attacks. Intermittent claudication is a clinical manifestation of peripheral vessel disease.
- the term “atherosclerotic disease event” as used herein is intended to encompass coronary heart disease events, cerebrovascular events, and intermittent claudication. It is intended that persons who have previously experienced one or more non-fatal atherosclerotic disease events are those for whom the potential for recurrence of such an event exists.
- the term “atherosclerosis related disorders” should be understood to mean disorders associated with, caused by, or resulting from atherosclerosis.
- hypertension includes essential, or primary, hypertension wherein the cause is not known or where hypertension is due to greater than one cause, such as changes in both the heart and blood vessels; and secondary hypertension wherein the cause is known.
- causes of secondary hypertension include, but are not limited to obesity; kidney disease; hormonal disorders; use of certain drugs, such as oral contraceptives, corticosteroids, cyclosporin, and the like.
- hypertension encompasses high blood pressure, in which both the systolic and diastolic pressure levels are elevated (>140 mmHg/>90 mmHg), and isolated systolic hypertension, in which only the systolic pressure is elevated to greater than or equal to 140 mm Hg, while the diastolic pressure is less than 90 mm Hg.
- Normal blood pressure may be defined as less than 120 mmHg systolic and less than 80 mmHg diastolic.
- a hypertensive subject is a subject with hypertension.
- a pre-hypertensive subject is a subject with a blood pressure that is between 120 mmHg over 80 mmHg and 139 mmHg over 89 mmHg.
- Treatment of hypertension refers to the administration of the compounds and combinations of the present invention to treat hypertension in a hypertensive subject.
- Treatment of hypertension-related disorder refers to the administration of a compound or combination of the present invention to treat the hypertension-related disorder.
- Prevention of hypertension, or a hypertension related disorder refers to the administration of the combinations of the present invention to a pre-hypertensive subject to prevent the onset of hypertension or a hypertension related disorder.
- the hypertension-related disorders herein are associated with, caused by, or result from hypertension. Examples of hypertension-related disorders include, but are not limited to: heart disease, heart failure, heart attack, kidney failure, and stroke.
- Dyslipidemias and lipid disorders are disorders of lipid metabolism including various conditions characterized by abnormal concentrations of one or more lipids (i.e., cholesterol and triglycerides), and/or apolipoproteins (i.e., apolipoproteins A, B, C and E), and/or lipoproteins (i.e., the macromolecular complexes formed by the lipid and the apolipoprotein that allow lipids to circulate in blood, such as LDL, VLDL and IDL).
- lipids i.e., cholesterol and triglycerides
- apolipoproteins i.e., apolipoproteins A, B, C and E
- lipoproteins i.e., the macromolecular complexes formed by the lipid and the apolipoprotein that allow lipids to circulate in blood, such as LDL, VLDL and IDL.
- Hyperlipidemia is associated with abnormally high levels of lipids
- Treatment of dyslipidemia refers to the administration of the combinations of the present invention to a dyslipidemic subject.
- Prevention of dyslipidemia refers to the administration of the combinations of the present invention to a pre-dyslipidemic subject.
- a pre-dyslipidemic subject is a subject with higher than normal lipid levels, that is not yet dyslipidemic.
- dyslipidemia related disorders and “lipid disorder related disorders” should be understood to mean disorders associated with, caused by, or resulting from dyslipidemia or lipid disorders.
- dylipidemia related disorder and lipid disorder related disorders include, but are not limited to: hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) levels, high plasma low density lipoprotein (LDL) levels, atherosclerosis and its sequelae, coronary artery or carotid artery disease, heart attack, and stroke.
- the term “obesity” as used herein is a condition in which there is an excess of body fat.
- the operational definition of obesity is based on the Body Mass Index (BMI), which is calculated as body weight per height in meters squared (kg/m 2 ).
- BMI Body Mass Index
- “Obesity” refers to a condition whereby an otherwise healthy subject has a Body Mass Index (BMI) greater than or equal to 30 kg/m 2 , or a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m 2 .
- An “obese subject” is an otherwise healthy subject with a Body Mass Index (BMI) greater than or equal to 30 kg/m 2 or a subject with at least one co-morbidity with a BMI greater than or equal to 27 kg/m 2 .
- An overweight subject is a subject at risk of obesity.
- a “subject at risk of obesity” is an otherwise healthy subject with a BMI of 25 kg/m 2 to less than kg/m 2 or a subject with at least one co-morbidity with a BMI of 25 kg/m 2 to less than 27 kg/m 2 .
- a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, has a BMI greater than or equal to 25 kg/m 2 .
- an “obese subject” refers to a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, with a BMI greater than or equal to 25 kg/m 2 .
- a “subject at risk of obesity” is a subject with a BMI of greater than 23 kg/m 2 to less than 25 kg/m 2 .
- obesity is meant to encompass all of the above definitions of obesity.
- Obesity-induced or obesity-related co-morbidities include, but are not limited to, diabetes mellitus, non-insulin dependent diabetes mellitus—type 2, diabetes associated with obesity, impaired glucose tolerance, impaired fasting glucose, insulin resistance syndrome, dyslipidemia, hypertension, hypertension associated with obesity, hyperuricacidemia, gout, coronary artery disease, myocardial infarction, angina pectoris, sleep apnea syndrome, Pickwickian syndrome, fatty liver; cerebral infarction, cerebral thrombosis, transient ischemic attack, orthopedic disorders, arthritis deformans, lumbodynia, emmeniopathy, and infertility.
- co-morbidities include: hypertension, hyperlipidemia, dyslipidemia, glucose intolerance, cardiovascular disease, sleep apnea, and other obesity-related conditions.
- Treatment of obesity and obesity-related disorders refers to the administration of the compounds of the present invention to reduce or maintain the body weight of an obese subject.
- One outcome of treatment may be reducing the body weight of an obese subject relative to that subject's body weight immediately before the administration of the compounds of the present invention.
- Another outcome of treatment may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy.
- Another outcome of treatment may be decreasing the occurrence of and/or the severity of obesity-related diseases.
- the treatment may suitably result in a reduction in food or calorie intake by the subject, including a reduction in total food intake, or a reduction of intake of specific components of the diet such as carbohydrates or fats; and/or the inhibition of nutrient absorption; and/or the inhibition of the reduction of metabolic rate; and in weight reduction in patients in need thereof.
- the treatment may also result in an alteration of metabolic rate, such as an increase in metabolic rate, rather than or in addition to an inhibition of the reduction of metabolic rate; and/or in minimization of the metabolic resistance that normally results from weight loss.
- Prevention of obesity and obesity-related disorders refers to the administration of the compounds of the present invention to reduce or maintain the body weight of a subject at risk of obesity.
- One outcome of prevention may be reducing the body weight of a subject at risk of obesity relative to that subject's body weight immediately before the administration of the compounds of the present invention.
- Another outcome of prevention may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy.
- Another outcome of prevention may be preventing obesity from occurring if the treatment is administered prior to the onset of obesity in a subject at risk of obesity.
- Another outcome of prevention may be decreasing the occurrence and/or severity of obesity-related disorders if the treatment is administered prior to the onset of obesity in a subject at risk of obesity.
- such treatment may prevent the occurrence, progression or severity of obesity-related disorders, such as, but not limited to, arteriosclerosis, Type II diabetes, polycystic ovarian disease, cardiovascular diseases, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, and cholelithiasis.
- the obesity-related disorders herein are associated with, caused by, or result from obesity.
- obesity-related disorders include overeating and bulimia, hypertension, diabetes, elevated plasma insulin concentrations and insulin resistance, dyslipidemias, hyperlipidemia, endometrial, breast, prostate and colon cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythms and arrythmias, myocardial infarction, congestive heart failure, coronary heart disease, sudden death, stroke, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich's syndrome, GH-deficient subjects, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity or a decrease in resting energy expenditure as a percentage of total fat-free mass, e.g, children with acute lymphoblastic leukemia.
- obesity-related disorders are metabolic syndrome, also known as syndrome X, insulin resistance syndrome, sexual and reproductive dysfunction, such as infertility, hypogonadism in males and hirsutism in females, gastrointestinal motility disorders, such as obesity-related gastro-esophageal reflux, respiratory disorders, such as obesity-hypoventilation syndrome (Pickwickian syndrome), cardiovascular disorders, inflammation, such as systemic inflammation of the vasculature, arteriosclerosis, hypercholesterolemia, hyperuricaemia, lower back pain, gallbladder disease, gout, and kidney cancer.
- the compounds of the present invention are also useful for reducing the risk of secondary outcomes of obesity, such as reducing the risk of left ventricular hypertrophy.
- metabolic syndrome also known as syndrome X
- syndrome X is defined in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III), National Institutes of Health, 2001, NIH Publication No. 01-3670. E. S. Ford et al., JAMA, vol. 287 (3), Jan. 16, 2002, pp 356-359.
- a person is defined as having metabolic syndrome if the person has three or more of the following disorders: abdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting plasma glucose. The criteria for these are defined in ATP-III.
- Treatment of metabolic syndrome refers to the administration of the combinations of the present invention to a subject with metabolic syndrome.
- Prevention of metabolic syndrome refers to the administration of the combinations of the present invention to a subject with two of the disorders that define metabolic syndrome.
- a subject with two of the disorders that define metabolic syndrome is a subject that has developed two of the disorders that define metabolic syndrome, but has not yet developed three or more of the disorders that define metabolic syndrome.
- administering should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to a human or other mammal in need of treatment.
- patient should be understood to mean a human or other mammal in need of treatment.
- the administration of the compound of structural formula I in order to practice the present methods of therapy is carried out by administering a therapeutically effective amount of the compound of structural formula I to the mammal (human or other mammal) in need of such treatment or prophylaxis.
- the need for a prophylactic administration according to the methods of the present invention is determined via the use of well known risk factors.
- the therapeutically effective amount of an individual compound is determined, in the final analysis, by the physician or veterinarian in charge of the case, but depends on factors such as the exact disease to be treated, the severity of the disease and other diseases or conditions from which the patient suffers, the chosen route of administration other drugs and treatments which the patient may concomitantly require, and other factors in the physician's judgment.
- Any suitable route of administration may be employed for providing a mammal, especially a human, with a therapeutically effective dose of a compound of the present invention.
- a mammal especially a human
- a therapeutically effective dose of a compound of the present invention for example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
- compounds of the present invention are administered orally.
- an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which may be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day.
- a suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day.
- compositions may preferably be provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
- the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
- the total daily dosage is from about 1.0 mg to about 1000 mg, preferably from about 1 mg to about 50 mg. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 350 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
- the compounds of this invention may be used in pharmaceutical compositions comprising (a) the compound(s) or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier.
- the compounds of this invention may be used in pharmaceutical compositions that include one or more other active pharmaceutical ingredients.
- the compounds of this invention may also be used in pharmaceutical compositions in which the compound of the present invention or a pharmaceutically acceptable salt thereof is the only active ingredient.
- composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- the compounds of the present invention may be useful in methods for the prevention or treatment of the aforementioned diseases, disorders and conditions in combination with other therapeutic agents.
- the compounds of the present invention may be useful in combination with one or more other drugs in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of formula I or the other drugs may have utility, where the combination of the drugs together are safer, more effective or more therapeutically effective than either drug alone.
- Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of formula I.
- a pharmaceutical composition in unit dosage form containing such other drugs and the compound of formula I is preferred.
- the combination therapy may also include therapies in which the compound of formula I and one or more other drugs are administered on different overlapping schedules.
- compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of formula I.
- DPP-4 dipeptidyl peptidase-IV
- active ingredients include, but are not limited to: (1) dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, omarigliptin, trelagliptin, teneligliptin, bisegliptin, anagliptin, vildagliptin, saxagliptin, alogliptin, melogliptin, linagliptin, gosogliptin, evogliptin, and gemigliptin), (2) insulin sensitizers, including (i) PPARy agonists, such as the glitazones (e.g.
- PPARu/y dual agonists e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar
- PPARU agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate)
- SPPARyM's selective PPARy modulators
- DPP-4 dipeptidyl peptidase-IV
- DPP-4 inhibitors include, without limitation, sitagliptin (disclosed in U.S. Pat. No. 6,699,871), omarigliptin, trelagliptin, teneligliptin, bisegliptin, anagliptin, LC15-0444, vildagliptin, saxagliptin, alogliptin, melogliptin, linagliptin, gosogliptin, evogliptin, gemigliptin, and pharmaceutically acceptable salts thereof, and fixed-dose combinations of these compounds with metformin hydrochloride, pioglitazone, rosiglitazone, simvastatin, atorvastatin, rosuvastatin, or a sulfonylurea.
- GPR-40 agonists that may be useful in combination with compounds of the formulas described herein include, but are not limited to: (1) 5-[4-[[(1R)-4-[6-(3-hydroxy-3-methylbutoxy)-2-methylpyridine-3-yl]-2,3-dihydro-1H-indene-1-yl]oxy]phenyl]isothiazole-3-ol 1-oxide; (2) 5-(4-((3-(2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)phenyl)phenyl)-methoxy)-phenyl)isothiazole-3-ol 1-oxide; and (3) 5-(4-((3-(2-methyl-6-(3-hydroxypropoxy)-pyridine-3-yl)-2-methylphenyl)methoxy)-phenyl)isothiazole-3-ol 1-oxide; and (4) 5-[4-[[3-[4-(3-aminopropoxy)-2,6-d
- Antiobesity compounds that may be combined with compounds of formula I include topiramate; zonisamide; naltrexone; phentermine; bupropion; the combination of bupropion and naltrexone; the combination of bupropion and zonisamide; the combination of topiramate and phentermine; fenfluramine; dexfenfluramine; sibutramine; lipase inhibitors, such as orlistat and cetilistat; melanocortin receptor agonists, in particular, melanocortin-4 receptor agonists; CCK-1 agonists; melanin-concentrating hormone (MCH) receptor antagonists; neuropeptide Y1 or Y5 antagonists (such as MK-0557); ⁇ 3 adrenergic receptor agonists; CB-1 receptor inverse agonists and antagonists; ghrelin antagonists; bombesin receptor agonists (such as bombesin receptor subtype-3 agonists); and 5-hydroxytryptamine-2c
- Glucagon receptor antagonists that may be useful in combination with the compounds of formula I include, but are not limited to: (1) N-[4-((1S)-1- ⁇ 3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl ⁇ ethyl)benzoyl]- ⁇ -alanine; (2) N-[4-((1R)-1- ⁇ 3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl ⁇ ethyl)benzoyl]-(3-alanine; (3) N-(4- ⁇ 1-[3-(2,5-dichlorophenyl)-5-(6-methoxy-2-naphthyl)-1H-pyrazol-1-yl]ethyl ⁇ benzoyl)-3-alanine
- Another embodiment of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising one or more of the following agents: (a) a compound of structural formula I; (b) one or more compounds selected from the group consisting of: (1) dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, omarigliptin, trelagliptin, teneligliptin, bisegliptin, anagliptin, vildagliptin, saxagliptin, alogliptin, melogliptin, linagliptin, gosogliptin, evogliptin, and gemigliptin); (2) insulin sensitizers, including (i) PPARy agonists, such as the glitazones (e.g.
- Specific compounds that may be useful in combination with a compound of the present invention include: simvastatin, mevastatin, ezetimibe, atorvastatin, rosuvastatin, sitagliptin, omarigliptin, metformin, sibutramine, orlistat, topiramate, naltrexone, bupriopion, phentermine, losartan, losartan with hydrochlorothiazide, olmesartan, canagliflozin, dapagliflozin, ipragliflozin and ertugliflozin.
- the above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds.
- Non-limiting examples include combinations of compounds with two or more active compounds selected from biguanides, sulfonylureas, HMG-CoA reductase inhibitors, PPARy agonists, DPP-4 inhibitors, anti-obesity compounds, and anti-hypertensive agents.
- the present invention may also provide a method for the treatment or prevention of a leukotriene B 4 receptor 1 (BLT1) mediated disease, which method comprises administration to a patient in need of such treatment or at risk of developing a BLT1 mediated disease of an amount of a BLT1 antagonist and an amount of one or more active ingredients, such that together they give effective relief.
- BLT1 leukotriene B 4 receptor 1
- a pharmaceutical composition comprising a BLT1 antagonist and one or more active ingredients, together with at least one pharmaceutically acceptable carrier or excipient.
- a BLT1 antagonist and one or more active ingredients for the manufacture of a medicament for the treatment or prevention of a BLT1 mediated disease.
- a product comprising a BLT1 antagonist and one or more active ingredients as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a BLT1 mediated disease.
- Such a combined preparation may be, for example, in the form of a twin pack.
- a compound of the present invention may be used in conj unction with another pharmaceutical agent effective to treat that disorder.
- the present invention may also provide a method for the treatment or prevention of diabetes, obesity, hypertension, Metabolic Syndrome, dyslipidemia, cancer, atherosclerosis, and related disorders thereof, which method comprises administration to a patient in need of such treatment an effective amount of a compound of the present invention and an amount of another pharmaceutical agent effective to threat that disorder, such that together they give effective relief.
- the present invention may also provide a method for the treatment or prevention of diabetes, obesity, hypertension, Metabolic Syndrome, dyslipidemia, cancer, atherosclerosis, and related disorders thereof, which method comprises administration to a patient in need of such treatment an amount of a compound of the present invention and an amount of another pharmaceutical agent useful in treating that particular condition, such that together they give effective relief.
- terapéuticaally effective amount or “a therapeutically effective dose” means the amount the compound of structural formula I that will elicit the biological or medical response of a tissue, system, animal, mammal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disorder being treated.
- the novel methods of treatment of this invention are for disorders known to those skilled in the art.
- mammal includes, but is not limited to, humans, and companion animals such as dogs and cats.
- the weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, a therapeutically effective dose of each will be used. Thus, for example, when a compound of the Formula I is combined with a DPIV inhibitor the weight ratio of the compound of the Formula I to the DPIV inhibitor will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
- 3,4-cis means 3S,4S or 3R,4R; 3,4-trans means 3S,4R or 3R,4S; Racemic trans or trans racemic or Rac-trans or rac-trans means a mixture of 3S,4R and 3R,4S; Racemic cis or cis racemic or Rac-cis or rac-cis means a mixture of 3S,4S and 3R,4R; Ac is acetyl; AcCN is acetonitrile; Ac 2 O is acetic anhydride; Alk is alkyl; anh. is anhydrous; aq or aq.
- PE petroleum ether
- PPA polyphosphoric acid
- i-PrOH is isopropanol
- Pd(OAc) 2 is palladium acetate
- Pd(PPh 3 ) 4 is tetrakis(triphenylphosphine)palladium
- P(Ph 3 ) 2 Cl 2 is bis(triphenylphosphine)-palladium (II) dichloride
- prep is preparative; prep. TLC or prep-TLC, or prep TCL is preparative thin layer chromatography; psi is pounds per square inch; rac is racemic; rt or r.t. or RT is room temperature; R f is retention factor; sat or sat.
- TLC thin-layer chromatography
- p-Tos, Tos and Ts are p-toluene sulfonyl
- TosCl and TsC1 are p-toluene sulfonyl chloride
- pTSA, pTsOH and TsOH are p-toluenesulfonic acid
- Ts 2 O is tosic anhydride orp-toluene sulfonic anhydride
- Xphos Pd G2 is chloro(
- Step 3 Mixture of (rac-cis)-7-bromo-3-(pyridin-2-ylmethyl)chroman-4-ol and (rac-trans)-7-bromo-3-(pyridin-2-ylmethyl)chroman-4-ol
- Step 5 (3S,4R or 3R,4S)-3-(pyridin-2-ylmethyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-ol
- Step 6 (3R,4S or 3S,4R)-3-(pyridin-2-ylmethyl)-7-(44,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-ol
- 1,1,1-Trifluoro-N-(2-(4-oxochroman-7-yl)phenyl)methanesulfonamide 350 mg, 0.943 mmol
- pyrrolidine 80 mg, 1.131 mmol
- benzaldehyde 120 mg, 1.131 mmol
- methanol 3 mL
- 1,1,1-Trifluoro-N-(2-(4-oxochroman-7-yl)phenyl)methanesulfonamide 330 mg, 0.89 mmol
- isonicotinaldehyde 150 mg, 1.4 mmol
- piperidine 1.5 mL
- acetic acid 1.5 mL
- the mixture was heated to 130° C. for 4 h. Then the solvent was removed under reduced pressure.
- the resulting crude material was dissolved in water (10 mL) and neutralized with saturated aqueous NaHCO 3 .
- the mixture was extracted with ethyl acetate (10 mL ⁇ 3), dried over Na 2 SO 4 and concentrated.
- the racemic mixture of Step 2 was purified by chiral SFC (IA column, 20%/80% methanol+0.25% dimethyl ethyl amine/CO 2 ) to afford 1,1,1-trifluoro-N-(2-((3R,4S or 3S,4R)-4-hydroxy-3-(pyridin-4-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide (Isomer 1, first eluting): MS ESI calcd.
- Step 2 1.1.1-trifluoro-N-(3-((3R,4S or 3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyrazin-2-yl)methanesulfonamide
- Step 2 N-(2-((3R,4S or 3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)-1-methylcyclopropane-1-sulfonamide
- Step 1 N-(6-chloro-4-((3R,4S or 3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridazin-3-yl)-1.1.1-trifluoromethanesulfonamide 89
- Step 2 1.1.1-trifluoro-N-(4-((3R,4S or 3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridazin-3-yl)methanesulfonamide 90
- Step 4 3-(1-(2-phenylthiazol-4-yl)ethyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) chroman-4-ol
- reaction was purged with N 2 gas for 10 min, followed by addition of 1,1′bis(diphenylphosphino)ferrocene]-dichloro-palladium(II) (26.4 mg, 0.036 mmol).
- the reaction mixture was heated to 80° C. for 14 h. Then the reaction solution was cooled to room temperature and concentrated. The resulting crude product was diluted with brine (10 mL) and extracted with EtOAc (2 ⁇ 10 mL).
- Step 5 1.1.1-trifluoro-N-(2-((3R,4S)-4-hydroxy-3-(1-(2-phenylthiazol-4-yl)ethyl)chroman-7-yl)phenyl)methanesulfonamide
- Step 6 Chiral Separation of Six Diastereomeric Single Enantiomers of 1.1.1-trifluoro-N-(2-((3R,4S)-4-hydroxy-3-(1-(2-phenylthiazol-4-yl)ethyl)chroman-7-yl)phenyl)methanesulfonamide
- a 100 mg potency tablet is composed of 100 mg of any one of the Examples, 268 mg microcrystalline cellulose, 20 mg of croscarmellose sodium, and 4 mg of magnesium stearate.
- the active, microcrystalline cellulose, and croscarmellose are blended first.
- the mixture is then lubricated by magnesium stearate and pressed into tablets.
- cAMP dynamic assay kit Cisbio Cat. No. 62AM4PEC
- HEK293 cells recombinantly expressing human BLT1, previously frozen in Recovery Medium (Life Technologies, Cat. No. 12648-010) were thawed and diluted into assay medium (HBSS (Hyclone SH 30268.01), 20 mM HEPES (Gibco 15630-106), 800 ⁇ M IBMX (Sigma 15879), 0.1% DTPA BSA (Perkin Elmer CR84-100)).
- HBSS Hyclone SH 30268.01
- 20 mM HEPES Gibco 15630-106
- 800 ⁇ M IBMX (Sigma 15879)
- 0.1% DTPA BSA Perkin Elmer CR84-100
- the cell suspension was centrifuged at 200 ⁇ g for 10 min and then resuspended in fresh assay medium to a density of 2.5 ⁇ 10 5 cells/mL.
- a Labcyte Echo 550 acoustic dispenser was used to transfer 25 nL of test compound dissolved in DMSO into the wells of a dry 384-well plate (Greiner 784075). All subsequent liquid additions were performed using a BIORAPTR (FRD; Beckman Coulter). Next, ⁇ L of cell suspension was added and incubated for 20 min. at 37° C. and 5% CO 2 in a humidified plastic tray. To test for agonist activity 5 ⁇ L of assay buffer containing forskolin (Sigma F-6886.
- cAMP-d2 vial was reconstituted with distilled water and then diluted accordingly with conjugate & lysis buffer. 5 ⁇ L of cAMP-d2 working solution was added to all of the wells of the assay plate.
- cAMP-Cryptate vial was reconstituted with distilled water and then diluted accordingly with conjugate & lysis buffer. 5 ⁇ L of cAMP-Cryptate working solution were added to the assay plate. The assay plate was shaken for 3 minutes and incubated at room temperature for 45 minutes, then read on Perkin Elmer Envision. cAMP standard curve and fit data were plotted using a 4 parameter dose response curve fitting algorithm to fit curve.
- a 4-parameter curve fit (Max, min, log EC50 and slope) was used to transform fluorescent 665 nm/615 nm ratio signal to cAMP concentration. After normalization to treated and untreated controls, the percent effect of signal at each compound concentration was calculated. The plot of percent effect versus the log of compound concentration was fit with a 4-parameter concentration response equation to calculate EC 50 values. Compound concentrations tested were 10 000, 3 333, 1 111, 370.4, 123.4, 41.2, 13.7, 4.6, 1.5 and 0.5 nM with 0.25% residual DMSO.
- the compounds of the present invention including the compounds in Examples 1-105, have EC 50 values less than ⁇ 5000 nanomolar (nM) in the BLT-1 cAMP Assay described above. Specific EC 50 values in the BLT-1 cAMP Assay are shown in Table I.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/768,880 US20190382363A1 (en) | 2015-11-30 | 2016-11-28 | Aryl sulfonamides as blt1 antagonists |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562260926P | 2015-11-30 | 2015-11-30 | |
PCT/US2016/063809 WO2017095724A1 (en) | 2015-11-30 | 2016-11-28 | Aryl sulfonamides as blt1 antagonists |
US15/768,880 US20190382363A1 (en) | 2015-11-30 | 2016-11-28 | Aryl sulfonamides as blt1 antagonists |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/063809 A-371-Of-International WO2017095724A1 (en) | 2015-11-30 | 2016-11-28 | Aryl sulfonamides as blt1 antagonists |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/343,994 Continuation US20220363656A1 (en) | 2015-11-30 | 2021-06-10 | Aryl sulfonamides as blt1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190382363A1 true US20190382363A1 (en) | 2019-12-19 |
Family
ID=58797922
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/768,880 Abandoned US20190382363A1 (en) | 2015-11-30 | 2016-11-28 | Aryl sulfonamides as blt1 antagonists |
US17/343,994 Pending US20220363656A1 (en) | 2015-11-30 | 2021-06-10 | Aryl sulfonamides as blt1 antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/343,994 Pending US20220363656A1 (en) | 2015-11-30 | 2021-06-10 | Aryl sulfonamides as blt1 antagonists |
Country Status (3)
Country | Link |
---|---|
US (2) | US20190382363A1 (de) |
EP (1) | EP3383868B1 (de) |
WO (1) | WO2017095724A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10370368B2 (en) | 2015-11-30 | 2019-08-06 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
EP3383869B1 (de) * | 2015-11-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Arylsulfonamide als blt1-antagonisten |
WO2017095722A1 (en) | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as blt1 antagonists |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939452A (en) * | 1994-10-13 | 1999-08-17 | Pfizer Inc | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4' (LTB4) antagonists |
CA2265209A1 (en) * | 1998-03-12 | 1999-09-12 | Pfizer Products Inc., | Method of preventing allograft rejection |
US6051601A (en) * | 1994-10-13 | 2000-04-18 | Pfizer Inc. | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists |
US10336733B2 (en) * | 2015-11-30 | 2019-07-02 | Merk Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
US10450309B2 (en) * | 2015-11-30 | 2019-10-22 | Merch Sharp & Dohme Corp. | Aryl sulfonamides as BLT1 antagonists |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215989A (en) | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
WO1993015066A1 (en) | 1992-01-23 | 1993-08-05 | Pfizer Inc. | Benzopyran and related ltb4 antagonists |
MX9300312A (es) | 1992-01-23 | 1993-07-31 | Pfizer | Antagonistas benzopiranicos y relacionado de ltb. |
WO1996006604A2 (en) | 1994-08-31 | 1996-03-07 | Eli Lilly And Company | Methods for identifying and treating resistant tumors |
EP0833664A1 (de) | 1995-06-12 | 1998-04-08 | G.D. SEARLE & CO. | Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen |
DE19637123A1 (de) | 1996-09-12 | 1998-03-19 | Boehringer Ingelheim Kg | Neue Pyranosidderivate |
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
WO1998039342A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
JP2001515482A (ja) | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−1,6−ビスホスファターゼの新規なベンズイミダゾールインヒビター |
WO2000014095A1 (en) | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
CA2415742A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
CA2434491A1 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
KR100454767B1 (ko) | 2001-07-19 | 2004-11-03 | 동화약품공업주식회사 | 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 |
ES2342596T3 (es) | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | Indoles con actividad anti-diabetica. |
AU2003260085B2 (en) | 2002-08-29 | 2008-09-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
WO2004066963A2 (en) | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
JP2010533712A (ja) | 2007-07-19 | 2010-10-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのベータカルボリン誘導体 |
US8093385B2 (en) | 2007-08-21 | 2012-01-10 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
ATE522500T1 (de) * | 2007-11-13 | 2011-09-15 | Renovis Inc | Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür |
US7989454B2 (en) | 2007-12-17 | 2011-08-02 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
US8093253B2 (en) | 2008-03-06 | 2012-01-10 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
ES2571452T3 (es) | 2012-01-10 | 2016-05-25 | Lilly Co Eli | Compuesto antagonista de leucotrieno B4 |
EP2936151B1 (de) * | 2012-12-18 | 2018-07-18 | BioCrine AB | Verfahren zur behandlung und/oder begrenzung von diabetes |
-
2016
- 2016-11-28 WO PCT/US2016/063809 patent/WO2017095724A1/en active Application Filing
- 2016-11-28 US US15/768,880 patent/US20190382363A1/en not_active Abandoned
- 2016-11-28 EP EP16871303.0A patent/EP3383868B1/de active Active
-
2021
- 2021-06-10 US US17/343,994 patent/US20220363656A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939452A (en) * | 1994-10-13 | 1999-08-17 | Pfizer Inc | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4' (LTB4) antagonists |
US6051601A (en) * | 1994-10-13 | 2000-04-18 | Pfizer Inc. | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists |
US6117874A (en) * | 1994-10-13 | 2000-09-12 | Pfizer Inc. | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4 ) antagonists |
CA2265209A1 (en) * | 1998-03-12 | 1999-09-12 | Pfizer Products Inc., | Method of preventing allograft rejection |
US10336733B2 (en) * | 2015-11-30 | 2019-07-02 | Merk Sharp & Dohme Corp. | Aryl acylsulfonamides as BLT1 antagonists |
US10450309B2 (en) * | 2015-11-30 | 2019-10-22 | Merch Sharp & Dohme Corp. | Aryl sulfonamides as BLT1 antagonists |
Also Published As
Publication number | Publication date |
---|---|
WO2017095724A1 (en) | 2017-06-08 |
US20220363656A1 (en) | 2022-11-17 |
EP3383868A4 (de) | 2019-05-15 |
EP3383868A1 (de) | 2018-10-10 |
EP3383868B1 (de) | 2022-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10100042B2 (en) | [5,6]—fused bicyclic antidiabetic compounds | |
US10662171B2 (en) | Antidiabetic bicyclic compounds | |
US10968193B2 (en) | Antidiabetic bicyclic compounds | |
US10131651B2 (en) | [7,6]-fused bicyclic antidiabetic compounds | |
US20220363656A1 (en) | Aryl sulfonamides as blt1 antagonists | |
US9834563B2 (en) | Antidiabetic substituted heteroaryl compounds | |
JP2022500470A (ja) | Lpaアンタゴニストとしてのシクロペンチル酸 | |
US10450309B2 (en) | Aryl sulfonamides as BLT1 antagonists | |
US10336733B2 (en) | Aryl acylsulfonamides as BLT1 antagonists | |
US10065945B2 (en) | Isoquinoline derivatives as MGAT2 inhibitors | |
EP2760855B1 (de) | Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und ihre verwendung bei der behandlung von typ-2 diabetes | |
US10370368B2 (en) | Aryl acylsulfonamides as BLT1 antagonists | |
US20230102520A1 (en) | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALBANY MOLECULAR RESEARCH, INC.;REEL/FRAME:045562/0229 Effective date: 20160621 Owner name: ALBANY MOLECULAR RESEARCH INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TUMMANAPALLI, SATYANARAYANA;REEL/FRAME:045562/0045 Effective date: 20160607 Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAN, YONGXIN;LIM, JONGWON;SILIPHAIVANH, PHIENG;AND OTHERS;REEL/FRAME:045561/0922 Effective date: 20160415 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |